Abstract
Background Canada may soon see the introduction of a national pharmaceutical insurance system. New Zealand has a government-funded healthcare system used by all residents that operates within a tight cost-containment budget.
Objective To compare the main mortality causes in Canada and New Zealand and examine listings in current Canadian provincial public drug plans and the New Zealand national drug formulary.
Methods Age-standardized mortality rates from 1985 to 2014 and data on hospital discharges and average length of stay in hospital for Canada and New Zealand were obtained from the Organization for Economic Cooperation and Development’s website. Information on insured medications was obtained from Canadian provincial drug plan lists and the New Zealand Pharmaceutical Schedule current in mid-2019.
Results Mortality rates for acute myocardial infarction, ischemic heart disease and cerebrovascular disease were higher, on average over the 30-year observation period, in New Zealand, but rates for malignancies and respiratory disorders were similar in the two countries. Reimbursement listing rates for drugs for cancer and some cardiovascular indications were lower in New Zealand than in Canada.
Conclusions New Zealand’s drug coverage system has contained costs, but it restricts or denies access to new innovative medicines with the potential to improve patients’ lives. Although a New Zealand-style national pharmacare scheme in Canada would offer the opportunity to restrain drug expenditure, it would likely fail to satisfy patients and healthcare providers and diminish health outcomes, resulting in higher costs in other healthcare sectors.
Competing Interest Statement
Funding The author gratefully acknowledges research funding for this work from Medicines New Zealand. Although Medicines New Zealand staff had the opportunity to review the manuscript, they had no control over the design, analysis or reporting of this work. Declaration of Conflicting Interests In the past three years, the author has received consultant fees from 3Sixty Public Affairs Inc and Fasken, research and publication fees from Advocacy Solutions, the Canadian Health Policy Institute, the Fraser Institute, Merck Sharp & Dohme (New Zealand) Ltd, RAREi (a collaboration of innovative pharmaceutical companies focused on the development of medicines for rare disorders) and Ward Health, publication processing expenses from BIOTECanada, Canadian PKU and Allied Disorders Inc and Shire Pharma Canada ULC, and honorarium and compensation for travel from La Fondation DEVENIR. No conflict of interest exists between these activities and the present work.
Funding Statement
The author gratefully acknowledges research funding for this work from Medicines New Zealand.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data derived from public domain resources.
